Human immunoglobulin potency determination is a critical quality control test that quantifies the concentration of functional specific antibodies in plasma-derived immunoglobulin products. This article provides a comprehensive technical overview of sample types, testing items, validated analytical methods, pharmacopoeial standards, and practical applications of potency testing in biologics manufacturing and batch release.
Technical Overview
Human immunoglobulin preparations are sterile biological products fractionated from pooled human plasma, and their clinical efficacy depends directly on the concentration of functional antibodies against specific pathogens. Potency determination, also referred to as titer measurement or antibody activity assay, is the quantitative analytical process used to verify that each manufacturing batch contains the minimum required level of protective antibodies. Regulatory authorities worldwide, including the National Institutes for Food and Drug Control (NIFDC), the European Directorate for the Quality of Medicines (EDQM), and the World Health Organization (WHO), mandate potency testing as a mandatory batch release criterion for all immunoglobulin products.
Potency results are expressed in International Units (IU) or International Units per milliliter (IU/mL), calibrated against WHO International Standards or regional standard reference materials. Because immunoglobulin products are biological rather than synthetic pharmaceuticals, inherent variability between plasma pools makes robust, standardized potency testing essential for ensuring patient safety and product consistency.
Testing Samples
Human Immunoglobulin for Intramuscular Injection
Conventional intramuscular immunoglobulin (IMIG) preparations are tested for general antibody content, typically including measles, rubella, hepatitis B surface antigen, and diphtheria antibody titers, to demonstrate adequate passive immunization capacity.
Human Immunoglobulin for Intravenous Infusion (IVIG)
Intravenous immunoglobulin products undergo potency determination for multiple pathogen-specific antibodies as part of identity and quality specifications. IVIG samples are also evaluated during stability studies to confirm that antibody activity is maintained throughout the shelf life.
Human Hepatitis B Immunoglobulin
Hyperimmune hepatitis B immunoglobulin (HBIG) products require precise anti-HBs antibody quantification, as clinical prophylaxis following needlestick exposure or perinatal exposure depends on achieving defined neutralizing antibody levels.
Human Rabies Immunoglobulin
Rabies immunoglobulin (HRIG) preparations are tested for rabies virus neutralizing antibody potency, since inadequate potency in post-exposure prophylaxis can result in fatal outcomes.
Human Tetanus Immunoglobulin
Tetanus immunoglobulin products require determination of tetanus antitoxin potency to guarantee effective neutralization of tetanus toxin in wound management prophylaxis.
In-Process and Stability Samples
In addition to finished products, potency testing is performed on plasma pools, fractionation intermediates, and samples held under accelerated and long-term stability conditions to support process validation and shelf-life justification.
Testing Items
The specific antibody potency items tested depend on the product type and its pharmacopoeial monograph. Common testing items include:
- Anti-hepatitis B surface antigen (anti-HBs) antibody potency, expressed in IU/mL
- Rabies virus neutralizing antibody potency, expressed in IU/mL
- Tetanus antitoxin potency, expressed in IU/mL
- Measles virus antibody titer
- Rubella virus antibody titer
- Diphtheria antitoxin antibody level
- Total IgG protein content and purity as supporting quality attributes
- Antibody potency retention during real-time and accelerated stability studies
Testing Methods
Potency determination methods are selected based on the target antibody, required sensitivity, and applicable pharmacopoeial requirements from the Chinese Pharmacopoeia (ChP), European Pharmacopoeia (Ph. Eur.), and United States Pharmacopeia (USP).
Enzyme-Linked Immunosorbent Assay (ELISA)
ELISA is the most widely used method for anti-HBs antibody potency determination. Samples and calibrated standards are reacted with hepatitis B surface antigen-coated plates, followed by enzyme-conjugated detection antibodies and colorimetric quantification. Results are calculated against a standard curve prepared using the WHO International Standard for anti-HBs immunoglobulin.
Fluorescent Antibody Virus Neutralization Test (FAVN)
The FAVN test is a gold-standard in vitro method for rabies virus neutralizing antibody determination. Serial dilutions of the sample are incubated with a fixed challenge dose of rabies virus, then inoculated onto permissive cell cultures. Residual infectious virus is detected by fluorescent antibody staining, and potency is calculated by comparison with the WHO International Standard for rabies immunoglobulin using probit analysis.
Rapid Fluorescent Focus Inhibition Test (RFFIT)
RFFIT provides a rapid alternative for rabies neutralizing antibody measurement, using fluorescent focus counting on cover-slip cell cultures to quantify virus neutralization. The method offers shorter turnaround time while maintaining acceptable correlation with FAVN results.
In Vivo Neutralization Assay
Historically referenced for tetanus antitoxin potency, the in vivo mouse neutralization test compares the ability of the sample and a standard antitoxin to protect mice against a standardized toxin challenge. Where validated, in vitro alternatives such as the toxin-binding inhibition (ToBI) assay or ELISA-based methods are increasingly accepted under the principles of the 3Rs (replacement, reduction, refinement).
Single Radial Immunodiffusion (SRID)
SRID, also known as the Mancini technique, quantifies antigen-antibody precipitation rings in agarose gel and is applied for specific antibody determination and total immunoglobulin quantification in certain product configurations.
Calibration and Reference Standards
All potency assays must be calibrated against recognized biological reference standards, such as WHO International Standards, European Pharmacopoeia Biological Reference Preparations, or national standard materials. Parallel-line bioassay statistical analysis or standard curve interpolation is applied, and assay validity criteria including linearity, precision, and reference standard bracketing must be satisfied before results are accepted.
Applications
Potency determination serves multiple critical functions across the lifecycle of immunoglobulin products:
- National batch release and lot-by-lot regulatory testing before market distribution
- In-process quality control during plasma fractionation and formulation
- Stability program support, demonstrating antibody activity retention through the approved shelf life
- Process validation and comparability studies following manufacturing changes
- Cold chain and distribution excursions impact assessment
- Pharmacopoeial compliance verification for import, export, and clinical trial materials
- Investigation of adverse event reports and product quality deviations
FAQ
What is the difference between potency and protein content in immunoglobulin products?
Protein content measures the total quantity of immunoglobulin present, while potency measures the functional activity of specific protective antibodies. A product may have adequate protein content yet fail potency testing if the specific antibody titer is insufficient.
Why are potency results expressed in International Units rather than mass units?
Biological activity cannot be precisely defined by mass alone because antibody preparations vary in binding affinity and neutralizing capacity. International Units provide a standardized, internationally harmonized measure of biological function traceable to WHO reference standards.
Which pharmacopoeial standards govern human immunoglobulin potency determination?
Testing is governed by the Chinese Pharmacopoeia, European Pharmacopoeia, and United States Pharmacopoeia monographs for human immunoglobulin and hyperimmune products, along with WHO guidelines for biological standardization.
What acceptance criteria apply to potency results?
Acceptance criteria are defined in each product specification and pharmacopoeial monograph. For example, hepatitis B immunoglobulin products must meet minimum anti-HBs potency requirements in IU/mL appropriate to their intended route of administration and clinical indication.
How is assay accuracy ensured across different laboratories?
Accuracy is ensured through the use of calibrated biological reference standards, validated assay protocols, participation in inter-laboratory proficiency testing programs, and compliance with Good Laboratory Practice (GLP) and data integrity requirements.